Results 11 to 20 of about 41,743 (197)

Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis. [PDF]

J Cosmet Dermatol
ABSTRACT Background Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non‐standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients.
Shu C, Zhang T, Liu JW, Zhu CY, Fang RY, Sun QN, Li N, Li F.   +7 more
europepmc   +2 more sources

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial. [PDF]

Arthritis Rheumatol
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Brunner HI, Alexeeva E, Bandeira M, Carrasco R, Chaitow J, Chiraseveenuprapund P, Ting TV, Erguven M, Gottlieb B, Oliveira SK, Patel PN, Ozen S, Saad Magalhaes C, Penadés IC, Gruben D, Germino R, Posner HB, Stockert L, Martini A, Lovell DJ, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG).   +21 more
europepmc   +2 more sources

Oral JAK Inhibitors as a Promising Therapeutic Strategy for Refractory Rosacea: A Systematic Review and Meta-Analysis. [PDF]

J Cosmet Dermatol
ABSTRACT Background Rosacea is a chronic inflammatory dermatosis. While standard therapies exist, managing refractory subtypes remains a therapeutic challenge. Oral Janus kinase (JAK) inhibitors have emerged as potential alternatives, but systematic evidence is lacking. Aims To evaluate the efficacy and safety of oral JAK inhibitors for rosacea through
Peng Y, Sun M, Chen J, Huang X, Zhang F.
europepmc   +2 more sources

Tofacitinib

DMW - Deutsche Medizinische Wochenschrift, 2014
Tofacitinib is the first Janus kinase inhibitor which was approved for the therapy of rheumatoid arthritis in the USA. Several phase III studies proved the efficacy of Tofacitinib as monotherapy or in combination with established medication. This article discusses the therapeutic potential of this new pharmacological approach and the current data on ...
Doeker, S., Dewenter, Matthias, El-Armouche, Ali   +2 more
openaire   +3 more sources

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Rheumatology and Therapy, 2022
Introduction This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. Methods Available data from phase 1, randomized phase 2/3/
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen   +14 more
doaj   +1 more source

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

RMD Open, 2021
Background Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib.Methods Data from two trials ...
Roy Fleischmann, Peter C Taylor, Kurt de Vlam, Joseph C Cappelleri, Alexis Ogdie, Lara Fallon, John Woolcott, Valderilio Azevedo, Andrew G Bushmakin   +8 more
doaj   +1 more source

Possibilities for the use of tofacitinib in patients with COVID-19

Качественная клиническая практика, 2020
No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some professional associations recommend discontinuing tofacitinib if SARS-CoV-2 infections is detected.
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev   +2 more
doaj   +1 more source

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Arthritis Research & Therapy, 2022
Background This study examined the time to clinically meaningful response in patients with active psoriatic arthritis treated with tofacitinib, adalimumab, or placebo switching to tofacitinib.
Dafna D. Gladman, Laura C. Coates, Joseph Wu, Lara Fallon, Elizabeth D. Bacci, Joseph C. Cappelleri, Andrew G. Bushmakin, Philip S. Helliwell   +7 more
doaj   +1 more source

Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2021
Objective: To explore the survival benefit of tofacitinib in addition to dexamethasone in hospitalized patients treated for coronavirus disease 2019 (COVID-19)–related pneumonia.
Maroun E. Hayek, MD, Michael Mansour, MD, Harrison Ndetan, MPH, MD, PhD, Quentin Burkes, PharmD, Robert Corkern, MD, Ammar Dulli, MD, Reya Hayek, BS, Karim Parvez, MD, Satwinder Singh, MD   +8 more
doaj   +1 more source

Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes

Acta Dermato-Venereologica, 2018
Tofacitinib is a Janus kinase (JAK) inhibitor, which has shown efficacy in treating psoriasis. The mode of action of tofacitinib is not completely understood but it has been thought to be mediated by the inhibition of CD4+ T-cell activation.
Ankit Srivastava, Mona Ståhle, Andor Pivarcsi, Enikö Sonkoly   +3 more
doaj   +1 more source